BMY Today - Aug 13: Merger Talk Fizzles Out
Impossibile aggiungere al carrello
Puoi avere soltanto 50 titoli nel carrello per il checkout.
Riprova più tardi
Riprova più tardi
Rimozione dalla Lista desideri non riuscita.
Riprova più tardi
Non è stato possibile aggiungere il titolo alla Libreria
Per favore riprova
Non è stato possibile seguire il Podcast
Per favore riprova
Esecuzione del comando Non seguire più non riuscita
BMY Today - Aug 13: Merger Talk Fizzles Out
-
Letto da:
-
Di:
So, what’s the scoop? BMY was trading around $64, and it felt like a slow day overall. The volume was pretty standard, nothing crazy. But there was some chatter in the air about merger talks involving AstraZeneca, and honestly, it seems like Wall Street wasn’t buying it. You know how that goes; when rumors fly around, people start reacting. But in this case, it looks like investors just shrugged it off.
Now, let’s talk about why BMY might be in the spotlight. They’ve got a growth portfolio that’s helping balance out some of the legacy pressures they’ve been facing. That’s a big deal because it shows they’re not just sitting around. They’re working on new stuff to keep the momentum going. But, on the flip side, some reports mentioned that BMY has been underperforming compared to its competitors. That one stung a bit, especially since everyone’s always looking for the next big thing in pharma.
Oh, and here’s a little nugget for you: Bristol-Myers also made some moves with Atrium Therapeutics, hitting them with a milestone payment of $15 million. So, they’re still making strides in the partnership game, which is always good to see.
To wrap it up, BMY had a decent day despite the mixed signals from the market and some chatter that didn’t really pan out. Just remember, stocks can be a wild ride, and it’s all about keeping your head in the game and staying informed. This is just for your info and entertainment, not financial advice. Catch you later!
adbl_web_anon_alc_button_suppression_t1
Ancora nessuna recensione